Sunday, 29 March 2020

Bio-Thera launches first Humira biosimilar in China

13 January 2020 | News

QLETLI® is Bio-Thera's first biosimilar to receive regulatory approval and is the second biosimilar approved in China by the NMPA

image credit- gettyimages.com

image credit- gettyimages.com

Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, has announced that QLETLI®, a biosimilar to Humira® (adalimumab), is now available in China. QLETLI® , the first adalimumab biosimilar approved by the China National Medical Products Administration (NMPA), is authorized for the treatment of three autoimmune diseases: rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis. QLETLI® is Bio-Thera's first biosimilar to receive regulatory approval and is the second biosimilar approved in China by the NMPA.

QLETLI® was approved based on the totality of evidence from a comprehensive data package supporting biosimilarity to adalimumab which includes analytical, nonclinical, pharmacokinetics, pharmacodynamics and clinical data. The Phase III clinical study met its primary endpoint showing no clinically meaningful differences in safety, immunogenicity and efficacy compared to adalimumab.

Bio-Thera Solutions is developing several additional proposed biosimilars, including biosimilars to Avastin® and to Actemra®/RoActemra®, which are both currently being evaluated in global Phase III clinical trials. Bio-Thera is also pursuing biosimilars to Simponi® and to Stelara®.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Are women in the industry getting the required recognition for their efforts?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls